Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10654873 | 0.90 | CYP1A2 (0.47) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL15312506 | 0.84 | SMN1; SMN2 (0.38) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL3423094 | 0.81 | ALOX5 (0.51) | SMN1; SMN2ALDH1A1LMNAPOLBALOX5 | |
| SCHEMBL1506449 | 0.79 | CYP1A2 (0.38) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL18095949 | 0.79 | CYP1A2 (0.46) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL10653733 | 0.78 | GAA (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL9831959 | 0.78 | CA12 (0.52) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL838165 | 0.78 | DNM1 (0.49) | CYP1A2ALDH1A1LMNATSHR | |
| SCHEMBL28497495 | 0.77 | MEN1 (0.39) | CA12CA1CA2CA9CYP1A2 | |
| SCHEMBL941055 | 0.76 | CA12 (0.37) | CA12CA1CA2CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2331544-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | Pfizer Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0275820-A2 | Unsaturated phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | CA12 4804/4885CA1 4645/4885CA2 3907/4885 |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | HSP90AB2P, HSP90AB1, HSP90AA1 | CA12 4790/4885CA1 4721/4885CA2 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.